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ABSTRACT 
BACKGROUND: Breast carcinoma, the most common malignant tumour among 
women contributes to a significant proportion of all cancers in women worldwide. It 
was graded based on levels of nuclear pleomorphism, tubular formation and mitotic 
index. The commonly used predictive immunohistochemical markers are estrogen 
receptors, progesterone receptors and HER2/neu status. In our study we use 
microarray technique where small representative tissue samples from many cases were 
assembled on a single histology slide and subjected to Immunohistochemical analysis.  
AIMS AND OBJECTIVES: To study histological grading by Modified Bloom 
Richardson grading system and ER, PR & HER 2/ neu status in invasive breast 
carcinoma by diagnostic immunohistochemistry using Manual Tissue Microarray and 
assess the cost-effectiveness of IHC done on TMA slides.  
MATERIALS AND METHODS: 50 cases of invasive breast carcinoma were 
included in the study. Histopathological examination of the haematoxylin and eosin 
stained slides were done and the tumour was graded according to Modified Bloom 
Richardson grading system. A standard method of microarray preparation was done. 
First the design for TMA construction was laid out. Paraffin embedded tissue blocks 
were collected and the areas of invasive carcinoma were cored from donor blocks and 
transferred to the recipient blocks using bone marrow needle. Thus tissue microarray 
was constructed manually.  Immunohistochemical analysis using ER, PR and 
Her2/neu were done for all these cases. Evaluation was done with Allred scoring 
system for ER and PR status, and ASCO guidelines for HER2/neu status.  
RESULTS: Of the 50 patients analysed, majority were invasive ductal carcinoma 
(84%). Majority of the invasive breast carcinoma were of MBR grade II (50%) 
followed by grade III tumors (42%) and grade I tumors (8%). Among 50 cases, ER 
and PR were positive in 24 cases (48%) and 31 cases (62%) respectively. HER-2/neu 
expression was seen in 25 cases (50%). A statistically significant correlation was 
noted between histologic grading and ER, PR and HER2/neu status. The tissue 
microarray uses only one seventh of the reagent consumed by conventional 
immunohistochemistry. 
 CONCLUSION: The process of immunohistochemistry using tissue microarray 
obviates the need for control and standardisation. This allows the study of different 
cases on a single slide, thus reducing the amount of reagent, duration and labour of the 
procedure and making it cost effective. Tissue loss due to technical problems can be 
overcome by following standard protocols or by obtaining more number of tissue 
cores. 
KEYWORDS: Breast carcinoma, Modified Bloom Richardson Grading, 
Immunohistochemistry, Tissue microarray.  
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INTRODUCTION 
Breast carcinoma is the most common malignant tumor among women. It 
contributes to a significant proportion of all cancers in women worldwide (25%).  
Annually about one million women are diagnosed with breast cancer 
worldwide(1). Breast cancer accounts for maximum number of deaths in the age 
group of 15-54 years(2).  
There is an increased trend in the detection of breast carcinoma, which 
can be attributed to increased mammographic screening and changes in 
lifestyle(3). But the mortality has decreased due to early screening, which detects 
the tumor at an early curable stage and also by means of  better effective 
treatment modalities. Nowadays the incidence of breast carcinoma has increased 
in less developed countries owing to gradual changes in lifestyle of women. 
Breast cancer is a heterogeneous disease with distinct biological subtypes. 
Major types includes invasive ductal carcinoma and invasive lobular carcinoma. 
Of these, invasive ductal carcinoma is the most common subtype accounting for 
70-80%,  it is further sub classified as well differentiated (grade1), moderately 
differentiated (grade2) and poorly differentiated (grade3) based on levels of 
nuclear pleomorphism, tubular formation and mitotic index(4). 
            The prognostic factors include  clinical variables  like age, menopausal 
status etc., and pathological variables like tumor size, histological type, 
histological grade and  lymph node status(5). 
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In addition to this there are certain predictive factors  like(6), 
1. Estrogen and progesterone receptor(ER, PR). 
2. HER2/neu amplification. 
3. Proliferative markers like Ki-67 
          The outcome of the tumor varies in each individual and is believed to be 
due to the heterogeneous nature of the tumor. 
 Tissue microarray is a recent innovation in the field of pathology. A 
microarray contains many small representative tissue samples from hundreds of 
different cases assembled on a single histologic slide and therefore allows high 
throughput analysis of multiple specimens at the same time, this can be 
subjected to Immunohistochemistry for analysis of carcinoma(7). This study is 
based on Histologic grading and Immunohistochemical analysis of ER, PR &  
HER 2/ neu status in invasive breast carcinoma for 50 cases using TMA. A 
major setback of IHC procedure is high cost of monoclonal antibodies and their 
limited shelf life which may be overcome by TMA. 
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AIM: 
To study  histologic grading by Modified Bloom Richardson grading 
system and ER, PR & HER 2/ neu status in invasive breast carcinoma by 
diagnostic Immunohistochemistry using Manual Tissue Microarray. 
 
OBJECTIVES: 
¾ To grade Invasive Breast carcinoma by Modified Bloom Richardson 
grading system. 
¾ To apply a panel of IHC markers on Invasive breast carcinoma.  
¾ To assess the time and cost effectiveness of  IHC done on TMA slides. 
¾ To standardize the procedure of manual TMA. 
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   REVIEW OF LITERATURE 
HISTORY:     
The first description of breast cancer dates back more than 3500 years. 
The Egyptians were the first to describe breast cancer as bulging tumor in breast 
.The descriptions of Edwin Smith and George Ebers Papyrus about breast tumors 
match with the present day scientific descriptions of breast cancer. The etiology 
of breast cancer was a matter of great speculation. Hippocrates was the first to 
describe breast cancer as a humoral disease and also named cancer as karkinos 
which is a Greek word for crab(8).  
EMBRYOLOGY 
The breast is a modified apocrine sweat gland and forms an important 
accessory organ of female reproductive system. 
The mammary glands develop at the fifth week of fetal development from 
the ectodermal mammary ridges which are present on the ventral surface of the 
fetus bilaterally from the axillary to the inguinal region. During the normal 
course of development majority of the mammary ridge disappears at the seventh 
week of gestation. 
          A small portion of the mammary ridge persists as primary mammary buds 
which are present in fourth or fifth intercostal spaces.  Development proceeds by 
the penetration of mesoderm by the primary buds of ectoderm. Eventually the 
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primary mammary buds develop into secondary buds at around 3rd month of 
gestation and the primary bud later contributes to mammary lobules. 
            At 20 weeks of gestation, the developing breast is penetrated by multiple 
radial ingrowths of ectoderm. This is followed by the canalization of the buds 
which are the precursors of the lactiferous ducts and their branches. The 
mammary pit which is formed during gestation by the convergence of the 
lactiferous ducts, then transforms into nipple during infancy. 
In males, there is no significant postnatal development of the breast but in 
females during puberty under the influence of sex hormones the parenchyma and 
the ductal system proliferates rapidly(9).  
ANATOMY 
            The breast is covered by skin and subcutaneous tissue and it lies on the 
pectoral muscle which is separated by a fascia. It extends from the 2nd to 6th    rib 
vertically and from the lateral border of sternum to the mid axillary line 
horizontally. A small extension called axillary tail of spence extends laterally 
towards the axilla. 
              The nipple lies at the level of 4th intercostal space and is pierced by           
15-20 lactiferous ducts. Surrounding the nipple is the areola which is a circular 
pigmented area and is rich in modified sebaceous glands.  Fibrous strands extend 
from the dermis into the breast, which attach the skin and nipple to the breast 
called the suspensory ligaments of Cooper. 
 
6 
 
  
Fig 1(A)-Diagramatic representation of Terminal Ducto-lobular unit 
 
The breast parenchyma is composed of glandular tissue which is arranged 
topographically into lobes. The lobes are made up of terminal duct lobular unit 
[TDLU] and the large duct system. The TDLU is the secretory portion of breast 
and consists of lobule and terminal ductule. Each lobule in turn is a cluster of 
acini. The TDLU connects with the lactiferous (collecting) duct by means of sub 
segmental and segmental duct. The lactiferous duct opens in to the nipple. A 
fusiform dilatation called the lactiferous sinus is present between the lactiferous 
and segmental duct [Fig 1(A)] (10).  
The intralobular stroma appears myxoid and envelopes the acini of the 
lobules and consists of   breast-specific hormonally responsive fibroblast-like 
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cells admixed with scattered lymphocytes. The interlobular stroma is made of   
dense fibrous connective tissue admixed with adipose tissue(10).  
BLOOD SUPPLY 
            Arterial supply of breast is by, 
i. Internal thoracic artery. 
ii. Branches of the lateral thoracic, superior thoracic and 
acromiothoracic arteries. 
iii. Lateral branches of posterior intercostal arteries. 
             Venous drainage of the breast follows the course of arteries forming an 
anastomotic circle in the subcutaneous tissue beneath the nipple-areola complex.  
From this the veins run as, 
1. Superficial veins draining into internal thoracic vein.   
2. Deep vein draining into internal thoracic, axillary and posterior intercostal 
veins(10).  
NERVE SUPPLY:  
Nerve supply is by anterior and lateral cutaneous branches of 4th and 6th 
intercostal nerves(10). 
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LYMPHATIC DRAINAGE 
1. Axillary lymph nodes: Lymphatic drainage is mainly into the anterior 
group of axillary nodes. Posterior, lateral, central and apical groups of 
nodes also receive lymphatic drainage either directly or indirectly. 
2. The internal mammary nodes which lies along internal thoracic vessels. 
3. Supraclavicular node, cephalic node, posterior intercostal, Sub  
diaphragmatic and sub peritoneal lymph plexus(10).  
4. The  superficial  lymphatics  drains overlying  skin of  breast  except 
nipple and areola .They  pass  radially  to  the  surrounding  lymph  nodes 
(axillary,  internal mammary,  supraclavicular  and  cephalic  node ). 
5. The deep lymphatics drain the parenchyma, nipple and areola of              
breast. About 75% of lymph drains into axillary nodes, 20% into internal 
mammary nodes and 5 % into posterior intercostal nodes(10). 
HISTOLOGY 
          The nipple and the skin are lined by the keratinizing stratified squamous 
epithelium. The entire ductal-lobular unit lies on a continuous basement 
membrane. It is lined by two cell layers: luminal epithelial cells and basally 
located myoepithelial cells [Fig 1(B)]. Luminal cells are either columnar or 
cuboidal depending on their function. Other cell types present in the breast 
include scattered endocrine cells(10).  
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Fig. 1(B) - Photomicrograph of Terminal Ducto-lobular unit in a normal 
adult female (H & E). 
The nipple is formed by the lactiferous duct along with the sebaceous 
unit. The main difference of epidermis of nipple and areola is the increased 
melanin content in basal layer compared to the normal skin. The basal layer also 
contains occasional Toker cells(10). 
Lactatory function of the breast is a co-ordinated effort of the lobular and 
myoepithelial cells. The secretory function is by the luminal cells in the lobules. 
The ejection of milk is by the contractile myoepithelial cells which also renders 
a structural support to lobules(10). 
When analyzed immunohistochemically the luminal epithelial cells stain  
positive  for keratin, EMA, lactalbumin, GCDFP-15. Myoepithelial cells are 
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positive for S-100, Smooth Musle Actin, calponin, caldesmon (duct portion) and 
also shows nuclear reactivity for p63(10). 
CARCINOMA BREAST 
Breast cancer is the most common malignant cancer among women(1). 
The incidence has increased nowadays due to increasing  awareness  of the 
people and use of diagnostic  modalities like mammography, fine needle 
aspiration and core biopsy(3). 
EPIDEMIOLOGY 
Breast cancer is one of the most prevalent diseases affecting women. 
Observation is that  the incidence of breast cancer has increased globally over 
the last several decades(11). And the more worrisome fact is that  the greatest 
increase has been in Asian countries(12). Worldwide, breast cancer is the most 
frequent cancer in women and represents the second leading cause of cancer 
death among women (after lung cancer)(13,14). The number of new cases 
occurring each year is estimated to be around 1,00,000(15). 
Breast cancer though a global disease does not have a uniform 
epidemiological pattern throughout. The age group of women affected varies 
like in Asia, breast cancer incidence peaks among women in their forties, 
whereas in the United States and Europe, it peaks among women in their sixties. 
Due to the early onset of disease in our part of the world, premenopausal patients 
constitute a larger proportion compared to western data(16). Even in India, breast 
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cancer is the commonest cancer in women in cities whereas in rural areas, it is 
second to cervical cancer. 
CLINICAL PRESENTATION 
Breast cancer can present in many different patterns. The most common 
symptoms are breast lump (60-70%) followed by pain (14-18%).Nipple 
discharge (7-9%) is the least common presenting symptom. With the 
introduction of mammographic screening there is an increased detection of 
asymptomatic cases. Anatomically upper outer quadrant contributes to majority 
of cases (40-50%) followed by central, upper inner, lower outer to lower inner 
quadrant(17).  
Breast mass should be evaluated by triple assessment which includes 
clinical examination, imaging studies (mammography, ultrasound) and tissue 
sampling either by fine needle aspiration cytology or core needle biopsy.(17) 
MICROSCOPIC TYPES 
1. Carcinoma In Situ 
2. Invasive Carcinoma 
INVASIVE DUCTAL CARCINOMA 
Whenever a tumor of breast shows a stromal invasion, it is described as 
invasive ductal carcinoma. Regardless of the presence of in situ component and 
the relative proportion of in situ and invasive component they are included under 
invasive carcinoma(10).  
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Two major categories of invasive carcinoma are - ductal and lobular type. 
Invasive ductal carcinoma comprises 75-85% of mammary carcinoma. Invasive 
ductal carcinoma, not otherwise specified comprises majority of duct carcinoma. 
Other relatively infrequent forms of infiltrating ductal carcinoma include tubular, 
medullary, metaplastic, colloid carcinoma etc(18).  
CYTOARCHITECTURAL TYPES 
1. INVASIVE DUCTAL CARCINOMA, NOS TYPE 
The major chunk of all breast carcinomas is comprised by IDC, NOS type 
(75 %). and is considered as the prototype of all breast carcinomas(19). 
GROSS:  
         The tumor is usually an ill circumscribed firm tumor. Cut section reveals a 
yellowish gray cut surface with multiple trabeculae radiating through the 
surrounding parenchyma in to the adjacent fat with a crab like or stellate 
configuration. In case of larger tumors, areas of necrosis, hemorrhage and cystic 
degeneration may be present. Scirrhous carcinoma was the term used 
synonymously with these tumors as they are hard in consistency due to large 
amounts of stroma. 
 MICROSCOPY:     
        The tumor shows various growth patterns like diffuse sheets, well defined 
nests, cords, trabeculae and also as individual cells. Glandular differentiation of 
the tumor varies from almost nil to well developed. The characteristic tumor 
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cells are usually large and pleomorphic. The tumor shows standard features of 
malignancy like prominent nuclei and nucleoli and increased mitotic figures. 
About 60% of the cases show areas of necrosis and calcification. The amount of 
stroma varies from scant to abundant desmoplastic stroma. The interphase 
between the tumor and stroma shows mononuclear cell inflammatory 
infiltrates(10).  
       Fisher et al. noted lymphatic, blood vessel and perineural invasion in 
33%, 5% and 28% of the cases respectively(20).  
IHC: 
         The tumor cells are positive for ER, PR, HER2/neu, low molecular weight 
keratin (8, 18 and 19) and EMA. Other sensitive breast related markers are 
mammoglobin and GCDFP 15.The basement membrane components collagen 4 
and laminin   shows a discontinuous linear pattern or it may be totally absent(10). 
2. INVASIVE CRIBRIFORM CARCINOMA 
           Invasive cribriform carcinoma is a rare form of breast malignancy which 
has an excellent prognosis.  
MICROSCOPY:  
The tumor shows a cribriform appearance similar to that of its intraductal 
counterpart but in addition it shows stromal invasion. Cribriform pattern is often 
seen in association with tubular formations. Page et al proposed that the relative 
proportion of the two elements determine the term to be used(21).  
14 
 
3. TUBULAR CARCINOMA 
Pure tubular carcinoma contributes only a small portion of invasive breast 
cancer. But in mammographic screening 9-19 % of cases are noted as speculate 
nature and cellular stroma which is characteristic of this tumor can be easily 
noted. 
GROSS:  
In gross section the tumor appears poorly circumscribed and is hard in 
consistency and the size of the tumor is usually small with a mean diameter of          
1 cm. 
MICROSCOPY:  
        The characteristic feature of tubular carcinoma is the irregular and 
angulated contour of the glands which shows no organoid configuration. The 
lining cells show apocrine type snouts in the apical cytoplasm. This tumor 
typically lacks myoepithelial cells and basement membrane. The lumina of the 
glands are open and filled with basophilic secretion. The tumor shows cellular 
desmoplastic reaction with fat invasion in the periphery. It can confused with 
benign disorders because of the well differentiated nature of the glands, scant 
pleomorphism and absence of necrosis(10). DCIS can be seen in majority of the 
cases. The in situ component is usually of low grade showing cribriform or 
papillary pattern.  
Since the tubular pattern in histopathology can be seen associated with  
invasive ductal carcinoma, NOS type  or sometimes with invasive lobular 
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carcinoma there can be a diagnostic dilemma. In such instances, the term tubular 
NOS and tubular mixed can be employed. The term tubular carcinoma can be 
best employed for tumors in which tubular pattern is present for at least 90 % of 
the tumor. These tumors are associated with favorable prognosis 
4. MUCINOUS CARCINOMA 
          Mucinous carcinoma was classified under mucin producing carcinoma.             
The age groups usually affected by this tumor are postmenopausal women. It is 
also called as mucoid, gelatinous or colloid carcinoma(17).  
GROSS: 
            The tumor is well circumscribed .Cut surface of the tumor shows a 
characteristic glistening and gelatinous appearance. 
MICROSCOPY: 
            The tumor cells are arranged usually in small clusters floating in a 
mucinous pool which are surrounded by bands of fibrous septa. The malignant 
cells are characterized by little pleomorphism and a low mitotic rate. The mucin 
is usually extracellular. 
Histochemically the mucins are o-acylated forms of sialomucin. 
Immunohistochemically there is strong MUC2 positivity in cytoplasm. Estrogen 
and progesterone receptors are always positive whereas HER2/ neu will be 
negative(22).  
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Two different types of mucinous carcinoma are seen based on the 
endocrine differentiation. Type A tumors shows trabeculae of malignant cells 
with minimal intracytoplasmic mucin. The cells are conspicuous by their 
absence of argyrophilia. Type B tumor shows sheets of tumor cells with 
abundant intracytoplasmic mucin with argyrophilia. 
        Nodal metastasis is very low which accounts for 2-4% of all cases. 
IHC:  
 They are positive for estrogen and progesterone receptors. They usually 
do not show HER2/neu overexpression or p53 accumulation. 
4. MEDULLARY CARCINOMA 
The tumor is most common in patients under 50 years of age and is 
common among carriers of BRCA1 mutation. 
GROSS: 
         The tumor is well circumscribed, solid and homogenous. 
MICROSCOPY:  
         The tumor grows in a diffuse pattern with minimal or absent glandular 
differentiation. The individual tumor cells are large, pleomorphic with large 
nuclei and prominent nucleoli. The distinct features of this tumor in microscopy 
are prominent lymphoplasmacytic infiltrate at the periphery of the tumor. The 
infiltrate was thought to be due to the reaction of host tissues to the neoplasm. 
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IHC: 
          They are positive for CK, p53 and negative for hormone receptors (ER, 
PR), Her2/neu and come under triple negative phenotype. The tumor expresses 
HLA-DR antigen which could be the possible reason for the prominent 
lymphoplasmacytic infiltrate. Though axillary lymph node involvement is 
common, only low axillary group of lymph nodes will be usually involved. The 
prognosis will be better than IDC, NOS type(10, 18).  
5.  ATYPICAL MEDULLARY CARCINOMA: 
     The tumor shows following characteristic features,  
a. Syncytial growth comprising  > 75% of the tumor 
b. Atypical features 
c. Focal tumor infiltration at the margins 
d. Uniform nuclei and rare mitosis 
e. Mild to absent lymphoplasmacytic infiltration at the margins. 
f. Focal tubule formation(23). 
 
6.  INVASIVE PAPILLARY CARCINOMA  
          The tumor is rare and occurs more frequently in the postmenopausal 
women.  Papillary carcinoma commonly present as in situ lesions. The invasive 
component can be papillary or it may show features of IDC, NOS type. As the 
presence of invasion in these tumors is not clear-cut, it should be applied only 
for cases with well differentiated true papillary structures. When a tumor with 
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papillary pattern is seen, metastatic papillary carcinoma from other sites should 
also be excluded(10, 18).  
            The tumor may have axillary lymph node metastasis particularly in solid 
variant of papillary carcinoma. Prognosis of the tumor is better compared to that 
of invasive ductal carcinoma, NOS type(24).  
7.  INVASIVE MICROPAPILLARY CARCINOMA 
Invasive micro papillary carcinoma is a distinct rare variant of invasive 
ductal carcinoma. When the micro papillary pattern is found throughout the 
tumor it is referred as pure invasive micro papillary carcinoma. When it is 
present as a part of conventional IDC it is called as mixed invasive micro 
papillary carcinoma. But the criteria to distinguish these two are not clear cut. 
Some authors suggest at least 50 % of the tumor should be micro papillary to 
call it as pure invasive micro papillary carcinoma. 
MICROSCOPY 
           The tumor is composed of clusters of cells arranged in micro papillary or 
tubular pattern and tumor cells are found floating in clear spaces. Fibro vascular 
core will be absent in the micro papillary clusters. The clusters exhibit a “inside 
out” arrangement in which the apical cells are polarized outside and this can be 
evidenced by MUC 1 staining. 
            The nuclear grade of this tumor cells will be high. About half of the cases 
may show psammoma bodies. In situ component seen in these cases is usually 
micro papillary and sometimes cribriform  pattern. 
19 
 
Lymphatic invasion is reported in more than 50 % of the cases. The tumor 
has a bad prognosis. 
IHC: 
In a study done by Cruz et al, estrogen receptor was positive in 72-75 % 
of cases, 45 % cases were positive for progesterone receptor and 36 % of the 
cases show Her 2-neu overexpression(25).  
8. APOCRINE CARCINOMA 
             Apocrine carcinoma is very rare comprising 0.5% of all breast 
carcinomas. The tumor is composed entirely or predominantly of apocrine type 
cells with tumor cells being large with abundant eosinophilic cytoplasm with 
vesicular nucleus and prominent nucleolus. Glandular differentiation can be seen 
with apocrine snouts. Diagnosis of apocrine carcinoma should only be made 
when the architectural features are those of a malignant tumor. 
Immunohistochemically they are positive for GCDFP-15.Estrogen and 
progesterone receptors will be negative(26).  
9. SECRETORY CARCINOMA 
Secretory carcinoma is a rare tumor and usually seen in children. It can 
also occur in adults and has an excellent Prognosis. 
GROSS: 
         The tumors are usually small and well circumscribed. 
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MICROSCOPY: 
          The tumor is composed of tubuloalveolar and papillary structures. The 
lumina contain eosinophilic PAS positive, diastase resistant material. The 
malignant cells have a pale staining vacuolated cytoplasm. Nucleoli may be 
prominent and mitosis is scanty. 
IHC: 
       There is a strong immunoreactivity for S-100 and a-lactalbumin. 
10. METAPLASTIC CARCINOMA 
Metaplastic carcinoma represents tumor predominantly with cell type 
other than epithelial and glandular component. It includes many categories 
which may overlap with each other.  Metaplastic carcinoma is more aggressive 
than invasive ductal carcinoma. Metastasis is usually hematogenous rather than 
lymph node metastasis. 
GROSS:  
The tumors are circumscribed and firm to hard in consistency. 
Degenerated cystic areas can be seen in cases with squamous metaplasia. Some 
of the tumors may have infiltrative borders. 
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CLASSIFICATION OF METAPLASTIC CARCINOMA 
TABLE 1: CLASSIFICATION OF METAPLASTIC CARCINOMA 
Purely epithelial Mixed epithelial and mesenchymal 
• Squamous - Large cell 
keratinizing, spindle cell, 
acantholytic 
• Adenocarcinoma with spindle cell 
differentiation  
• Adenosquamous, including 
mucoepidermoid 
 
• Carcinoma with chondroid 
metaplasia 
• Carcinoma with osseous 
metaplasia 
• Carcinosarcoma 
 
A. SQUAMOUS CELL CARCINOMA 
GROSS 
The tumors are large showing cystic spaces filled with keratin. 
MICROSCOPY: 
           In pure squamous cell carcinoma the central cystic cavity is lined by 
malignant squamous cells. Most cases represent squamous metaplasia. 
         Other two variants which can be seen are acantholytic squamous cell 
carcinoma and adenosquamous carcinoma. Low grade adenosquamous 
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carcinoma is said to have a favourable prognosis whereas acantholytic squamous 
cell carcinoma has an aggressive behavior(27).  
B. CARCINOSARCOMA 
When the transition between sarcomatous and carcinomatous component 
is gradual and sharp, it is termed carcinosarcoma. Microscopically the sarcoma 
like component can be malignant fibrous histiocytoma, osteosarcoma, 
chondrosarcoma, angiosarcoma or a combination of various components.  
          When the transition to cartilaginous or osseous elements is direct without 
an intervening spindle cell component or osteoclastic giant cells, it is called 
matrix producing carcinoma.   
IHC: 
         The sarcoma like elements acquires vimentin and other mesenchymal 
features which is referred to as the phenotypic switch. The cells are occasionally 
positive for epithelial markers. 
SPREAD RELATED VARIANTS 
1. INFLAMMATORY CARCINOMA 
The diagnosis of inflammatory carcinoma is essentially based on clinical 
criteria. Clinically the entire breast is red, warm mimicking mastitis. The mastitis 
like appearance is due to carcinomatosis of dermal lymphatic vessels. Skin 
biopsy is usually performed to reveal dermal lymphatic permeation. 
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Histopathological examination of some of the cases shows an undifferentiated 
carcinoma. 
          The prognosis is usually bad. Studies done by Charafe-Jauffret et al. found 
that most of the inflammatory carcinomas are negative for estrogen and positive 
for MIB1, E-Cadherin and HER2/ neu(28).  
INVASIVE LOBULAR CARCINOMA: 
1. CLASSIC TYPE 
It is the most typical form of Invasive Lobular Carcinoma which is 
characterized by the presence of small, uniform tumor cells which grows singly, 
in Indian file and in a concentric fashion around lobules. The stroma is usually 
abundant, of dense fibrous type(10, 18).  
2. PLEOMORPHIC LOBULAR CARCINOMA  
This form of invasive breast tumor has the pattern of growth of a classic 
breast carcinoma but exhibits a marked degree of nuclear pleomorphism and 
abundant cytoplasm. It also frequently shows apocrine differentiation, focal 
signet ring morphology. 
IHC:  
These tumors lack hormone receptors with higher expression of P53 and 
HER2/neu. They occasionally express chromogranin, but lack E-cadherin 
staining(10).  
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3. HISTIOCYTOID CARCINOMA 
Histiocytoid carcinoma is characterized by a diffuse growth of tumor cells 
which displays abundant granular, foamy cytoplasm. It may simulate the 
appearance of a granular cell tumor (myoblastoma). It is currently viewed as a 
variant of invasive lobular carcinoma exhibiting apocrine differentiation. 
IHC:  
Immunohistochemical reactivity for GCDFP-15 and the demonstration of 
mRNA for the related prolactin-inducible protein (PIP) by in situ hybridization. 
In most cases E-cadherin is absent. The mucins expressed by this tumor include 
some ‘non-mammary’ types, such as MUC2 and MUC5AC(10).  
4. SIGNET RING CARCINOMA  
Signet ring carcinoma is a type of breast carcinoma in which the tumor 
cells show intracytoplasmic mucin accumulation, resulting in the typical signet 
ring appearance. It is important to separate this tumor from mucinous carcinoma 
(in which the mucin is extracellular). 
IHC:  
Signet ring carcinoma is positive for CK7 and MUC1, and usually 
negative for E-cadherin. 
5. TUBULOLOBULAR CARCINOMA  
This variant is characterized by the admixture of small tubular formations 
having a minute or undetectable lumen (‘closed’ or ‘almost closed’ tubules) with 
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cords of tumor cells growing in a lobular configuration similar to that of invasive 
lobular carcinoma. The in situ component, if present, may be of lobular, ductal 
or mixed type. It is associated with a higher incidence of multifocality and 
positive axillary nodes than pure tubular carcinoma 
IHC:  
Immunohistochemical profile is intermediate between those of ductal and 
lobular carcinoma, in that it shows positivity for both E-cadherin and HMW 
keratin(10, 20).  
HISTOLOGICAL GRADING OF DUCTAL CARCINOMA 
           Grading of breast cancer was first attempted by Greenhough in 1925(29). It 
was an extensive system with 18 features and it is not used now. In 1993 
Haagensen evaluated 15 histological features which mainly include growth 
pattern, cell morphology and the stromal reaction. 
           The most popular grading system till date was proposed by Bloom in 
1950(30). The original classification proposed by him was based on three main 
features which include degree of tubule formation, nuclear features and mitotic 
activity. He classified breast carcinomas into 2 group low grade and high grade 
tumors. 
             In 1957 this classification was upgraded by modifications of Bloom and 
Richardson .without changing the features of classification, he included score of 
1 to 3  to each criteria according to mild ,moderate or marked degrees. A total 
score of 3 to 9 was given as follows(31),  
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TABLE 2:  BLOOM AND RICHARDSON GRADING SYSTEM 1957 
 
Elston further modified this classification by applying this only to 
invasive ductal carcinoma and excluding special types like mucinous, medullary 
carcinoma. Elston and Ellis modified Bloom and Richardson grading system by 
quantifying the mitotic activity(32). This is also referred as the Nottingham 
modification of  Bloom  and  Richardson system. 
TABLE 3: NOTTINGHAM MODIFICATION OF BLOOM 
RICHARDSON HISTOLOGICAL GRADING SYSTEM 
Score          3-5      Grade 1 Well differentiated tumors 
Score         6-7    Grade 2 Moderately differentiated tumors 
Score         8-9    Grade 3 Poorly differentiated tumors 
CRITERIA SCORE 
Tubule and gland formation 
Majority of tumor (>75%) 
Moderate degree (10-75%) 
Little or none (< 10% ) 
 
1 
2 
3 
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Mitotic count 
Mitotic count is also graded as 1-3. But it depends on the field diameter 
used. Mitotic figures are to be counted from the most mitotically active area. 10 
high power fields should be counted from the same area. Poorly preserved area 
should be ignored. 
TABLE 4: SCORING OF MITOTIC COUNT 
Field diameter 0.59mm Field diameter 0.44mm Score 
0-9 0-5 1 
10-19 6-10 2 
>20 >11 3 
 
 
 
Nuclear pleomorphism 
Small, regular, uniform 
Moderate variation in size, shape 
Marked  variation in size, shape 
 
1 
2 
3 
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TABLE 5: FINAL GRADE OF NOTTINGHAM MODIFICATION OF 
BLOOM RICHARDSON HISTOLOGICAL GRADING SYSTEM 
GRADE SUM OF POINTS 
I 3–5 
II 6–7 
III 8–9 
 
PROGNOSTIC FACTORS 
1. Age 
Prognosis is better in patients <50 years. Older patients have a higher rate 
of recurrence and distant metastasis. 
2. Pregnancy 
             Carcinoma breast manifesting during pregnancy is generally aggressive 
with over expression of HER2/neu and low expression of hormone receptor. 
3. BRCA-1 status 
Tumors associated with BRCA1 mutation carriers have a low survival 
rate. 
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4. Skin and nipple invasion 
T4a lesions are associated with decreased survival rate. Nipple 
involvement is associated with high incidence of axillary node metastasis(33). 
5. Presence or absence of invasion 
The single most important prognostic determinator of breast carcinoma is 
the presence of invasive component. The invasive component of a tumor 
correlates with the nodal metastasis. The in situ component is proportionate to 
the incidence of multicentricity and indirectly with occult metastasis(10). 
6. Size of the tumor 
Tumor diameter should be measured in three planes to the nearest      
millimeter. The greatest diameter is taken as the size of the tumor. For lesions 
less than 1 cm stage micrometer is used in histological sections for tumor size 
estimation. The invasive component is the better predictor of the total tumor size 
than the DCIS component. 
It has been proved beyond doubt that tumor size correlates with the 
prognosis. Multivariate analysis by Nottingham/Tenovas Primary Breast cancer 
study showed tumor size is an independent prognostic variable(34).  
7. Histological type 
The variants of invasive ductal carcinoma with a better prognosis than 
IDC, NOS type are tubular carcinoma, cribriform carcinoma, medullary 
carcinoma, papillary carcinoma, pure mucinous carcinoma and secretory 
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carcinoma. Signet ring cell carcinoma in particular is associated with a poor 
prognosis. 
8. Histological grade 
The poorer the grade of the tumor by Nottingham modification of the 
Bloom–Richardson system, the worse is the outcome, particularly IDC, NOS 
type(35).  
9. Tumor necrosis 
Spontaneous tumor necrosis is associated with tumors showing high 
histological grade and   increased incidence of lymph node metastases(36) and 
hence a poorer prognosis. 
10. Lymphovascular emboli 
              Presence of tumor emboli within endothelial lined spaces in the 
peritumoral area under H & E is taken as positive lymphovascular invasion. 
Lymphatic emboli within the breast correlate with local recurrence and vascular 
invasion correlates with distant spread(37).  Tumors with vascular emboli have a 
poor prognosis. 
11. Lymph node status 
Lymph node involvement is an important prognostic factor(38). The better 
method for lymph node assessment is by histopathology than clinical 
assessment. Many studies showed that patients with regional node involvement 
have a bad prognosis than those without node involvement. 
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Ten year survival rate for node negative patients will be 75 % while 
compared to that only 25-30% in node positive patients. Prognosis is also 
dependent on the number and the level of regional lymph nodes. The prognosis 
will be poor if greater number of nodes is involved(39).  
NSABR categorises patients under two divisions for therapeutic purpose. 
They are categorized as patients with 1-3 positive nodes and cases with 4 or 
more positive nodes. 
12. Hormone receptors 
Estrogen receptor positive tumors have a longer disease free survival. 
13. HER2 /neu expression 
               HER2 / neu over expression correlate with the tumor grade. It has a 
poor prognosis especially when associated with lymph node metastasis. It is an 
excellent predictor of response to the drug trastuzumab but a weak predictor for 
chemotherapy(40).  
14. Cell proliferation 
Cell proliferation has emerged as an important parameter especially in 
node positive patients. Tumors with increased proliferation rate behave 
aggressively. The   simple  method  to  assess  proliferation  will  be  the  mitotic  
count .Nowadays  Ki 67 has been  used  to  determine  cell  proliferation  by 
immunohistochemistry(41). Other methods include flow cytometry, S phase 
fraction. 
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15. Microvessel density. 
               Invasive breast carcinoma with prominent vascular component in the 
surrounding stroma behaves aggressively than other tumors(42).  
HORMONE RECEPTORS 
The presence of hormone receptors (estrogen, progesterone) correlates 
with the response of the tumor to endocrine therapy and chemotherapy. Though 
estrogen and progesterone are codependent variables, estrogen receptor status is 
the powerful predictive factor in breast cancer management(43).  
ER and PR are expressed in 80 % and 60 % of the breast cancer, 
respectively. There is not much correlation between receptor positivity and cyto 
architectural type of breast. But however some studies suggest that mucinous, 
tubular, lobular carcinoma show high estrogen positivity. Medullary, apocrine, 
metaplastic carcinomas are estrogen negative(44).  
There are two parameters evaluated in immunohistochemical assessment of 
hormone receptors which include, 
• Number of tumor cell nuclei stained-expressed as percentage of entire 
tumor nuclei population. 
• Intensity of the reaction 
These hormone receptors are measured semiquantitatively. There are 
various scoring systems like Quick score, H score and Allred score with Allred 
score is the most established score these days. It consists of a score for intensity 
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(0 to 3) and a score for the proportion of nuclear staining (0 to 5). The final score 
is obtained by the sum of proportion score and intensity score which ranges from 
0 to 8. Invasive tumor with an Allred score of more than 2 was considered to be 
positive for hormonal receptors(45).  
Estrogen and Progesterone receptors 
  The ovarian hormones, primarily estrogen are believed to play a role in 
breast cancer etiology. These steroid hormones influence their effect on breast 
cell proliferation by the estrogen receptor (ER) and progesterone receptor (PR). 
The estrogen receptor is expressed in two different types, usually referred to as α 
and β. They are encoded by gene ESR1 and ESR2 on the sixth and fourteenth 
chromosome (6q25.1 and 14q), respectively(46). The main function of the 
estrogen receptor is as a DNA binding transcription factor, which regulates gene 
expression(47).  
      The binding of estrogen to ER stimulates proliferation of mammary cells, 
resulting in increase in cell division and DNA replication leading to mutations. 
Secondly, estrogen metabolism produces genotoxic waste. Both processes lead 
to disruption of cell cycle, apoptosis and DNA repair, progressing to tumor 
formation. This is the proposed mechanism of effects of estrogen on breast 
cancer. ER-α is certainly associated with more differentiated tumors, while   
evidence of ER-β involvement is controversial(48).  
The source of estrogens is not only endogenous but the use of exogenous 
estrogen, such as oral contraceptives and hormone replacement therapies (HRT), 
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also triggers this cell proliferation process. Hunter et al. have studied this effect 
of oral contraceptives as sources of exogenous estrogen for the increased risk of 
breast cancer for women using these products(49). Estrogen receptor status is an 
important diagnostic parameter when a patient presents with breast cancer. 
Patients are classified as either estrogen receptor positive (ER+) or estrogen 
receptor negative (ER-) based on immunohistochemistry of the biopsy sample 
for ER-α. 
The introduction of adjuvant hormonal therapy, in particular tamoxifen, 
has been one of the major breakthroughs in the fight against breast cancer 
mortality. 
For women with estrogen receptor (ER)-positive breast cancer, 5 years of 
tamoxifen in an adjuvant setting decreases the risk of death. The same effect 
cannot be said for ER-negative patients as risk of death from breast cancer was 
significantly increased in those treated with tamoxifen(50). 
Progesterone an ovarian steroid hormone plays a key role in the 
development and functioning of the mammary gland. As with other steroid 
hormones, the action of progesterone is mediated through its intercellular 
receptor, the progesterone receptors (PR) which function as a transcription factor 
that regulates gene expression. The tumorigenic effect of progesterone is 
mediated by mutation or aberrant expression of the coregulators which affect the 
normal function of the PR and may lead to breast cancer(51).  
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The prognostic significance of elevated PR levels is that these tumors are 
less aggressive tumors. The other good prognostic feature is that they are 
associated with a longer overall survival time in metastatic disease, whereas PR 
negative tumors are more aggressive(52). The American Society of Clinical 
Oncology (ASCO) recommended that ERα and PR should be measured on every 
primary invasive breast cancer. 
Human Epidermal growth factor Receptor 2 (HER-2/neu)  
HER-2 (Human Epidermal growth factor Receptor 2) also known as 
proto-oncogene Neu .The oncogene neu is so-named because it was derived 
from a rodent glioblastoma cell line, which is a type of neural tumor. HER-2 
protein is known to form clusters in cell membranes that might play a role in 
tumorigenesis(53). HER cellular signalling occurs through transmembrane 
receptor tyrosine kinases and can induce cell proliferation, motility, and 
invasion. Dysregulated expression and activity of HER family members is 
prevalent in human neoplasia. Overexpression of this protein leads to 
constitutively activated tyrosine kinase, resulting in mitogenic transduction and 
poorer prognosis(54).  
Approximately 10% to 34% of invasive breast cancers overexpress the 
HER2 receptor and are referred to as HER2-positive HER2+(55).  Overexpression 
is associated with poor prognosis as well as with aggressive tumor growth and 
metastases. 
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It also occurs in other cancers such as ovarian cancer, stomach cancer, 
and uterine cancer(56). The American Society of Clinical Oncology (ASCO) 
recommended that should be determined Her-2 as a part of diagnostic routine on 
every primary invasive breast cancer. 
Studies show that HER2/neu is an independent prognostic indicator for 
overall survival of patients with breast carcinoma. 
IMMUNOHISTOCHEMISTRY  
Immunohistochemistry is one of the powerful ancillary methods used in 
pathology today which has revolutionized the study of disease and its prognosis. 
The most useful aspect of IHC is that it is a powerful and cost effective tool 
applicable in light microscopy. The morphologic observations made by 
pathologists are validated by the use of IHC. Immunohistochemistry (IHC), or 
immunocytochemistry, is a method for localizing specific antigens in tissues or 
cells based on antigen-antibody recognition(57).  
 The main advantages of IHC which makes it a good companion to 
pathologist are, it can be done in regular laboratories under light microscope 
without specialized devices. Standard fixation techniques can be used and it is 
permanent which can be done on archival material with additional benefit of  
good sensitivity and specificity(58). 
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USES OF IHC: 
¾ Classifying undifferentiated tumors, lymphomas, neuroendocrine and soft 
tissue tumors.  
¾ Detection and accurate assay of tumor biologic factors of prognostic and 
predictive values such as hormone receptors (ER, PR) and HER-2/neu in 
breast cancer.  
¾ Detection of metastatic cells in bone marrow, lymph nodes& serous fluids 
when the cell groups are too less or confusing.  
Clearly the validity of immunohistochemistry in diagnostic 
histopathology depends in great measure on the quality of immunostains. In 
addition to antibody quality, three other factors have a major impact on 
immunohistochemistry. 1. Tissue fixation and processing. 2. Unmasking of 
epitopes. 3. Sensitivity of detection system. Among the various available 
fixatives, formaldehyde is the most popular because of its low cost, ease of 
preparation, and because it preserves morphologic details with few artifacts. 
However, formaldehyde fixation results in a variably reversible loss of 
immunoreactivity by its masking or damaging some antibody binding sites.  
              IHC is performed in formalin fixed paraffin embedded tissue blocks. 
The results were interpreted based on Allred scoring system for ER, PR and by 
using the American Society of Clinical Oncology/College of American 
Pathologists (ASCO/CAP) guidelines for HER 2(59). 
 
38 
 
TABLE 6: ER, PR SCORING BY IMMUNOHISTOCHEMISTRY 
(ALLRED SCORING SYSTEM) 
% of cells 
positive 
score Staining 
intensity 
Score 
0 0 - - 
< 1 1 Mild 1 
1 – 10 2 Moderate 2 
11 – 33 3 Intense 3 
34 – 66 4   
67 – 100 5   
 
TOTAL SCORE =PROPORTION SCORE + INTENSITY SCORE  ( 0 TO 8) 
 
INTERPRETATION: 
 0, 2 - Negative 
≥ 3 - Positive  
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TABLE 7: GRADING OF THE IMMUNOHISTOCHEMICAL STAINING 
FOR HER 2 / NEU OVEREXPRESSION 
Score Staining Pattern HER 2 / neu protein 
overexpression assessment 
0 
 
No staining at all or very slight partial 
membrane staining in less than 10% of 
tumor cells. 
Negative 
1+ 
 
Faint barely perceptible membrane staining 
in more than    10%     of tumor cells. Cells 
stained in only part of the membrane. 
Negative 
2+ 
 
Weak to moderate complete membrane 
staining observed in more than 10% of 
tumor cells. 
Weakly Positive 
3+ Strong complete membrane staining in more  
than 30% of tumor cells 
Strongly Positive 
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MOLECULAR SUBTYPE OF BREAST CARCINOMA 
In the year 2000 Perou and colleagues tried to segregate breast carcinoma 
based on their gene expression profiles into distinct subgroups. They used 
microarray to demonstrate gene expression. It was accepted with a hope that this 
will provide new approach to the biology of breast cancer and was also believed 
that it may impact on the therapeutic approach of the patient(60).  
             The subtypes recognized by the gene expression are luminal A, luminal 
B, HER2/neu type, basal like and normal breast like. It was suggested that 
normal breast like subtype is most propably an artifact rather than genuine 
subtype. It is due to lack or sparsity of tumor in the tissue samples used for 
microarray analysis. 
As the different subtypes show specific characteristics, they may benefit 
from different therapeutic approach. Among the subtypes, basal like type shows 
the worst prognosis(60).  
LUMINAL A 
         It comprises 50% of the invasive breast cancer. This is seen in tubular 
carcinoma, cribriformcarcinoma, low grade invasive ductal carcinoma NOS type 
and classic lobular carcinoma. It expresses luminal cytokeratins and hormone 
receptors. They respond well to chemotherapy and have good prognosis. 
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LUMINAL B 
        It comprises 20% of invasive breast carcinoma. It corresponds to invasive 
ductal carcinoma NOS type and micropapillary carcinoma. It expresses 
cytokeratins with moderate to weak expression of hormone receptors. 
Proliferation rate is higher compared to that of luminal A type. It shows variable 
expression for chemo and endocrine therapy. 
HER 2/NEU 
         It comprises about 15% of invasive breast cancer. The tumors are usually 
high grade with lymph node metastasis. They are negative for hormone 
receptors. HER2/neu amplification and high proliferation is seen. Patients 
respond to trastuzumab and anthracycline based chemotherapy and usually have 
a poor prognosis. 
BASAL LIKE 
It comprises about 15% of invasive breast carcinoma. High grade IDC 
NOS, metaplastic and medullary carcinoma come under this category. They are 
negative for hormone receptors and HER2/neu but show a high proliferation 
rate. 
               An effort is also made to classify the tumors based on the 
immunnohistochemical expression. The panel of markers include estrogen 
receptor (ER), progesterone receptor, HER2/neu, EGFR, cytokeratin 5/6 and 
Ki67.   
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Based on the reactivity they are classified as follows, 
TABLE 8: MOLECULAR TYPING OF BREAST CARCINOMA 
ACCORDING TO EXPRESSION OF IHC MARKERS 
Immuno profile Luminal A Luminal B HER2/neu Basal-like 
ER, PR 
ER and/or 
PR+ 
ER and/or 
PR+ 
ER–, PR– ER–, PR– 
HER2 and others 
HER2 – 
Low Ki-67 
(<14%)  
HER2+ or 
HER2 – 
Ki-67 =14%  
HER2+ 
HER2– 
CK5/6 and/or 
EGFR+ 
 
        But this classification has some drawbacks. Relatively small number of 
cases are used do define molecular subtypes and few less common distinct 
subtypes are missed out. The basal like subtype also contains tumors with 
favourable prognosis like medullary carcinoma, secretory carcinoma which 
show the need of a low grade basal like subtype. Currently the clinical value of 
molecular classification is not well established(61).  
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TISSUE MICROARRAYS  
Dr. Hector Battifora introduced a new technique in 1986 in which a 
number of tissues from various organs are thrown into the same block and tissue 
distribution of a particular antigen was processed. This was called sausage block 
technique(62). Wan et al in a modification of the original technique produced a 
library of paraffin embedded cores and used it to determine various staining 
patterns of many number of monoclonal antibodies(63). Later this was modified 
by Kononen et al who introduced the term ‘Tissue microarray’ in 1998 which is 
widely used nowadays, which includes the usage of 4mm skin biopsy punch 
needle(64).  
The major focus of TMAs at the present time is in the fields of cancer and 
non-cancer research; and quality control in modern pathology(65). It has greatly 
facilitated the in situ analysis of molecular targets at the DNA, mRNA, and 
protein levels under standardized conditions in a large number of archived 
pathology specimens(66).  
One of the major advances of the technique is the ability to perform a 
variety of studies like immunohistochemistry, fluorescence in situ hybridization 
(FISH), or RNA in situ hybridization (ISH) in a very cost effective manner(67). 
The common application of microarray technique is for immune staining 
markers such as p53, bcl2, HER2, E-cadherin, ER, PR, Ki67 and others(68). 
Despite the flexibility and benefits of this method, its broader use has been 
hampered because of the technical difficulties of array construction and the costs 
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of available arrayers. The specialized commercial automated and semi- 
automated equipments as well as the inexpensive simple manual tissue array 
methods have been used to construct the TMA blocks(69). The cost of available 
arrayers and technical difficulties of routine array construction have limited the 
development of tissue microarray technique in developing countries like 
India(70). 
The disadvantages associated with this technique are that the small size of 
TMA cores may not be representative of the whole heterogeneous cancers and 
may not provide enough data about the entire tissue profile(71). The technical 
issues commonly noted with the application of microarray technique are 
sectioning difficulties, irregular cutting plane due to variable thickness of donor 
paraffin blocks, core losses and instability of the TMA blocks in routine TMA.  
This technology thus offers a way to fill the gap between the discovery of 
new molecular markers, derived from high throughput genomic analysis, and 
their application in the clinical setting. 
Materials for TMA 
The sources of the material for construction of Tissue microarray varies 
widely and are categorized based on material of origin. They are called simply as 
Tissue microarrays are constructed from paraffin embedded materials and can 
also be constructed using resin as recipient block, if very thin sections are 
required(72). But the construction of resin Tissue microarray is very difficult 
when compared to paraffin Tissue microarray(73). Tissue microarrays can also be 
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constructed using frozen sections in which case they are called as Cryoarrays  or 
and can be constructed using paraffin embedded cell lines and by using cell 
blocks(74). 
TMA categorization 
Tissue microarray is categorised based upon the usage of instruments and 
purpose of tissue microarray. Based upon the usage of the instruments and 
microarrayer used it has been classified into manual, semi-automated and 
automated tissue microarray. There are many instruments which are available 
nowadays which includes, the manual and automated tissue arrayer from 
Beecher instruments, the semi-automated tissue arrayer from Veridiam, the 
quick ray manual and the automated tissue arrayer from Unitma and the manual 
array mold tissue arrayer. Apart from this many number of home- made tissue 
arraying methods have been published(75, 76).  
The common feature between all these devices is that they use hollow 
needles or punches and they adopt the technique of skin biopsy to extract tissue 
cores from a donor block and make a new paraffin recipient block. After cutting 
all the tissue cores appear as circular samples arranged in grid like fashion. 
The initial step which is considered most important in construction of 
Tissue microarray is to clearly define the purpose of Tissue microarray 
construction and to decide the number and size of the tissue core which should 
be taken from the donor block. Then blocks and slides of the selected cases are 
carefully reviewed to mark the area of interest. The method of tissue sampling 
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varies widely from tissue to tissue. If task is to compare the expression pattern of 
a marker from tumor centre and periphery, the cores from the particular location 
may be compatible. However the method of tissue sampling is entirely different 
when the task is to characterize the overall expression of the protein in a tumor. 
Targeted sampling technique is followed in the cases of comparing the 
expression patterns of tumor centre and periphery whereas Random sampling 
technique is best suited to study the overall expression patterns(77). 
.  
Fig. 2(A) shows taking out a tissue core from the donor block with skin 
biopsy needle. 
 
          Tumor heterogeneity, which results in differential expression of different 
tumor cell, has been recognized as the potential problem in tissue sampling for 
the construction of Tissue microarray. Taking multiple samples from each tumor 
or area of interest appears to be the best technique to overcome this problem(78). 
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Although no standard and universally agreed sampling methods are in the 
records, it is intuitive when more samples are taken it becomes the representative 
area for donor tissue. The concordance of Tissue microarray technique with full 
section eventually depends upon the number of cores obtained. Most of the 
studies seem to indicate that the results from triplicate Tissue microarray cores 
have upto 98% concordance with the results from full section. However Goethal 
through his study suggests that atleast four cores are needed to achieve greater 
accuracy of more than 95% which is obtained using two core tissue sampling 
method(79).  
It should be also noted that there are also technical reasons which 
increases number of cores taken from each tissue block(80). The reasons being, 
tissue folding and complete loss of tissues during processing and section cutting. 
Total number of lost cases accounts for as high as 23% in the Tissue microarray 
construction study by using tissue cores from the cases of renal cell 
carcinoma(81). There are controversial data regarding the size of the cores that 
should be used in Tissue microarray technique and their influence over the 
technique. 
The next critical step included in tissue microarray is designing the layout 
of the tissue microarray. There are no general agreements regarding the 
designing of optimal layout of a tissue microarray. As there are problems of 
staining artefacts when performing immunohistochemistry in the full sections, 
the use of protection wall in the Tissue array technique is recommended as 
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introduced by Hoose et al, which uses a row of tissue cores which will not be 
analysed and can be any tissue that is available in plenty in the laboratory(82). 
Any confusion in identifying the origin of the cores after Tissue microarray 
construction makes the staining and analysis very difficult and hence orientation 
of the tissue cores needs to be perfect. Many use orientation cores in the specific 
position, usually outside the geometric margin of the array. Using the 
intentionally left empty core position, it is possible to identify and orient the 
position of the cores macroscopically as well as to orient cut section 
microscopically. In addition insertion of control tissue array may be of more 
value in orientation of the tissue cores. Thus the control core serves as an 
orientation control and also as both internal positive and negative control(83).  
Recipient blocks are nothing but the empty paraffin blocks that are 
prepared by pouring the soft molten wax into existing metal moulds of varying 
size. The major difficulty encountered in using metal moulds is the formation of 
air bubbles within the recipient blocks during the cooling procedure. The air 
bubbles which are formed during the process of cooling will not be evident 
apparently and not be identified till the section cutting. The subsequent 
sectioning of Tissue microarray causes severe distortion of constructed array and 
leads to difficulties during the steps of interpretation and analysis. To minimize 
this kind of problem and as a quality control measure, all the recipient blocks are 
subjected to X-ray by using Faxitron machine before Tissue microarray 
construction and if air bubbles are found the recipient blocks are melted for 
reuse. The use of moulds which are made from paper and plastic may reduce the 
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problem of bubble formation which is commonly encountered when paraffin 
recipient blocks are used(83).  
Tissue Arrayers 
Both automated and manual tissue arrayers are available for the 
construction of Tissue microarray. Automated tissue arrayers are easy to use. 
The instrument usually marks, edits and saves punch co-ordinates by using an on 
screen display and software tools. Automated tissue arraying instruments are 
commonly used in laboratories with high volume of Tissue microarray and can 
punch upto 180 cores/hour. 
Automated HT-1 Tissue Microarray 
Automated Tissue microarray is a highly potential and efficient technique 
which can be used to study gene expression. At present TMA has become a 
standard research platform for the histopathological analysis. This technique 
involves the acquisition of multiple core biopsies from area of interest from the 
donor block and transferring it into the recipient paraffin blocks with the help of 
special instrument. This includes collection and selection of donor blocks to be 
analysed, identifying the area of interest and representative areas, preparation 
and making array pores in the recipient paraffin blocks, punching tissue 
cylinders from the area of interest from the donor block, insertion of  cylinders 
containing tissues into the recipient blocks and embedding and cutting of newly 
formed Tissue microarray. However most important of all these steps is the 
construction of tissue microarray blocks using commercially available 
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instruments. The key steps in automated tissue microarray are punching array 
pores in recipient blocks and embedding multi-tissue cylinders into the recipient 
blocks(84).  
Recipient block formation 
This method uses three types of recipient block maker which are called as 
recipient block-molding machine  that can accommodate 24, 42, 56 tissue 
cylinders. The spacing between the cores is usually fixed. Recipient paraffin 
blocks can be made within several seconds by using block-molding machine. 
The instrument is composed of an array pores forming metal tamp series of 
metal embedding boxes and punch needles with corresponding inner cores. The 
array pores-metal consist of metal plates and a bracket. The lower plate is fixed 
with hollow cores while upper plate is fixed with inner cores. The inner diameter 
is designed from 0.5 to 2.5mm.The instrument for making array recipient blocks 
is fixed in the manipulator with the help of the bracket. The lower plate with the 
hollow array can move up and down by controlling the handle. The residual 
paraffin in array hollow punch is automatically removed by the piston(84).  
Negative-pressure embedding 
Negative pressure embedding instrument is designed to re-embed the 
multi-tissue cylinders into the recipient block for the construction of Tissue 
microarray. It is composed of negative pressure room, vacuum pump and an 
embedding box. The embedding box is situated in the negative pressure room 
and is connected to the vacuum pump through the tube. The bottom of the 
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embedding box consists of metal mesh, which can effectively adjust the negative 
pressure so that the air bubbles which are formed can be drained out of recipient 
paraffin blocks. Screen mesh can also be used to adjust the temperature for the 
embedding media(84).  
TMA without prefabricated recipient block 
Array construction done with the help of automated tissue arrayers proved 
to be very costly and hence not suitable in developing laboratories. Hence 
efficient microarray system which is cost effective was designed using manual 
tissue arrayer technique. Most of the manual methods used pre constructed 
paraffin recipient block into which holes are punched followed by insertion of 
tissue cores. The use of paraffin blocks proved difficult because of block 
breakage during punching, non alignment of holes, and mismatch between the 
size of the recipient hole and the tissue core. With the desire to overcome these 
difficulties, TMA construction was done without the use of prefabricated 
paraffin blocks(85). 
This technique followed the method which was initially modified by 
Kononen et al. A disposable skin punch biopsy needle of 2mm diameter was 
used for punching cores from the donor blocks. A long steel wire with a blunt 
end was modified into a stylet. The skin biopsy needle has the sharp cutting edge 
and a uniform cylindrical core. Double sided adhesive tapes, pair of stainless 
steel forceps, paper cutters, embedding mould and plastic cassettes are the 
additional requirements of this technique. A piece of double sided adhesive tape 
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is cut according to the size of embedding mould and the top surface is exposed 
to receive the tissue cores. The site for the attachment is marked with the ruler 
and the felt pen. The area to be cored is marked on the block by superimposing 
the marked area over the slides. After obtaining the core from the donor block, 
the core is transferred to adhesive tape using the forceps. Then it is transferred to 
stainless steel mould and after which melted paraffin wax is poured. Later after 
uniform setting of the block the adhesive tape is peeled off to expose the cutting 
surface. This method can give rise upto 20 sections from each core. This is 
reliable, readily reproducible and does not need any specialisation(85).  
Simple manual Tissue Microarray 
This is the modification of conventional manual tissue microarray which 
used skin punch biopsy needle. This technique used bone marrow aspiration 
needle for the construction of manual tissue microarray. Both 14 gauge and 16 
gauge needles are used. After the selection of donor block, the area of interest is 
marked and empty recipient paraffin block is made using the mould. By using 
16gauge needle pores are made in the recipient block(85).  
Then with the help of 14 gauge needle tissue cores are obtained from the 
area of interest from the donor block and then inserted into the recipient block. 
The smaller diameter (16G) of the needle used to punch the blank paraffin wax 
block allowed the bigger tissue cores (14G) to fit exactly into the blank. Once 
the array is complete hot liquid paraffin is poured over the array surface and the 
53 
 
tissue cylinders are levelled with the blocks using a glass slide. Then the array is 
incubated at 600c for 15 minutes after which the array is chilled on ice [fig 2(B)].  
 
Fig. 2(B) – shows the final recipient paraffin block 
 
Types of TMA based on application 
The technique of tissue microarray can be classified based on the purpose 
of Tissue microarray construction. Random arrays contain tissue from multiple 
sites including both tumoral and non-tumoral tissues. This is most widely used 
for monitoring the efficacy of the existing antibodies. Cell line arrays consist of 
normal and cancer cell lines that are grown in cultures. The main purpose of 
using this array is to analyse the utility of an antibody in detecting the proteins. 
Outcome based arrays are the most valuable and the most difficult to construct 
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as they involve the collation of  tissues from the patients of same disease, those 
who were exposed to similar pattern of treatment and have been followed up for 
significant period. Progression arrays are used in analysis of role of proteins in 
the progression of cancer. Tumor characteristic based array is constructed based 
on the given characteristics such as patient age and tumor grade(83).  
The use of tissue microarrays has its own advantages and disadvantages. 
Tissue microarray allows the performance of tissue based array such as 
immunohistochemical analysis, histochemistry and in situ hybridisation on a 
very large number of sample in a cost effective manner [fig 2(C)]. Several 
different tissues from a number of patients can be examined in short period using 
TMA. Automated Tissue microarrayers are very quick and manual tissue arrays 
are simple to construct and cost effective. The major disadvantage of using 
Tissue microarray is that each tissue core obtained from the selected donor block 
represents only a fraction of the lesion. But this can be overcome by taking 
multiple cores usually from various sites(83). Hence Tissue microarray can be 
considered as one of the superior and more advantageous technique used in 
studying tissue biology.  
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Fig. 2(C) – Tissue Array slide stained with Immunostain for estrogen 
receptor (ER) 
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MATERIALS AND METHODS 
 
 The study was conducted after obtaining approval from Institutional 
Ethical Committee of Tirunelveli Medical College, Tirunelveli. The study was 
carried out in the Department of Pathology, Tirunelveli Medical College and 
Hospital, Tirunelveli from January 2014 to September 2015.  
SOURCE 
Formalin fixed, paraffin embedded tissue blocks from 50 surgically 
resected breast tissues which were diagnosed as invasive breast carcinoma by 
histopathological examination were retrieved along with their haematoxylin and 
eosin stained slides and they were examined and the tumor was graded according 
to Modified Bloom and Richardson grading system. 
SAMPLE SIZE 
 A total of 50 cases were included in this study. Clinical data like patient 
age, sex and other relevant history were noted from the Pathology records. 
INCLUSION CRITERIA 
• Invasive ductal carcinoma - NOS type 
• Papillary carcinoma 
• Medullary carcinoma 
• Mucinous carcinoma 
• Tubular carcinoma 
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• Metaplastic carcinoma  
• Invasive lobular carcinoma 
EXCLUSION CRITERIA 
• Benign tumors of breast. 
• Ductal carcinoma in situ. 
• Lobular carcinoma in situ 
MATERIALS REQUIRED 
1. Lay out for constructing Tissue microarray. 
2. Metal moulds and molten wax for preparing empty recipient paraffin 
block. 
3. Donor blocks which contain formalin fixed paraffin embedded tissue 
obtained from all the cases of Invasive breast carcinoma. 
4. Hematoxylin and eosin stained tissue sections made from the donor 
blocks. 
5. Black glass marking pen for marking area of interest. 
6. 16 gauge bone marrow aspiration needle for making punches in the 
recipient block and 14 gauge needle for obtaining core from the donor 
block. 
7. Microtome and incubator for obtaining tissue sections and to dewax the 
sections  
8. Positively charged slides for holding tissue sections for IHC. 
9. Chemicals for preparing antigen retrieval solutions and for wash buffers. 
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10. Pressure cooker for antigen retrieval. 
11. Kit for performing immunohistochemistry which includes primary 
antibody (ER, PR & HER 2 neu) and universal kit. Microscope, used for 
interpretation and grading of IHC. 
METHODOLOGY 
The method of performing immunohistochemistry over the paraffin tissue 
microarray includes the following steps. 
1. Designing the layout for TMA construction. 
2. Collection of the donor blocks. 
3. Preparation of the recipient paraffin blocks. 
4. Immunohistochemistry and analysis. 
DESIGNING THE LAY OUT 
Before constructing the array proper, the layout of the tissue microarray 
defining the geometric position of each tissue core in the recipient block is made. 
The grid is constructed in such a way that there was a single core from each case 
on the recipient block. The grid had blank cores in between the cores from the 
cases which helped in determining the position of the cases on the 
immunohistochemistry performed slides. 
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COLLECTION OF THE DONOR BLOCKS 
The hematoxylin and eosin stained sections which were prepared from 
formalin fixed paraffin embedded blocks of all the cases of invasive breast 
carcinoma in the Department of pathology during the study period were 
retrieved. The corresponding formalin fixed paraffin embedded tissues were also 
obtained which constituted the donor block. Then the hematoxylin and eosin 
stained slides which contained full sections were examined and the area of 
interest was marked by using black glass marking pen. The area of interest is the 
area of tumor containing well preserved and well stained malignant cells. Then 
these marked areas on the slides were matched with the donor blocks and the 
corresponding areas over the donor blocks were also marked with the help of 
black glass marking pen. This area was used as the site for obtaining cores for 
the recipient block. 
PREPARATION OF THE RECIPIENT PARAFFIN BLOCKS 
The empty paraffin recipient blocks with minimum size of 25mm x 
25mm were first prepared by freshly poured molten wax in the metal moulds. 
Then it was allowed to cool. Later using 16 gauge needle, paraffin wax cylinders 
of 2mm diameter were punched from the recipient blocks. Each block contained 
3x3 cylinder matrix at a distance less than 2mm. In our study seven such blocks 
containing 50 cases were prepared.  
Then using 14gauge bone marrow aspiration needle, tissue cylinders were 
obtained from the area of interest which were previously marked over the the 
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donor blocks, after which it was injected into the recipient blocks into the 
corresponding empty cylinders with the help of  predesigned layouts so that six 
recipient blocks contained seven cases and one recipient block contains eight 
cases. After the recipient block was embedded with the tissue cores, the block 
was incubated at 400c for 15 minutes and then it was allowed to cool for few 
minutes at room temperature and then the array was chilled on the ice for few 
minutes.  
IMMUNOHISTOCHEMISTRY  
SECTION CUTTING 
            Sections were taken at 5 microns thickness after tissue microarray 
construction on the surface of the Poly-L-Lysine coated slides. This was 
followed by incubation of slides at 58-600c for one hour. 
ANTIGEN RETRIEVAL SOLUTION 
We used two antigen retrieval solution and a wash buffer as prescribed by 
the manufacturer (PATH IN SITU). 
1. Citrate buffer at a pH of 6.2 for HER 2/ neu. 
2. Tris EDTA at a pH of 9 for ER, PR. 
3. Tris wash buffer at pH of 7.6 for both. 
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ANTIGEN RETRIEVAL 
In our institution we followed antigen retrieval by using pressure cooker 
as it produces even heating with lesser disadvantages compared to other 
methods.  
PROCEDURE FOR IMMUNOHISTOCHEMISTRY AS GIVEN BY 
MANUFACTURER 
1. Section cutting and incubation is followed by Xylene wash (2 changes) 
for 10 minutes each. 
2. Rehydrated in graded alchohol containing 100%, 80%, 70% for ten 
minutes each. 
3. Rinsed in distilled water for 2 minutes. 
4. Antigen retrieval. 
5. Cooling for 15 minutes. 
6. Washed in TRIS wash buffer- 2 changes 5 minutes each. 
7. Treated with peroxide block for 5 minutes. 
8. Washed in TRIS wash buffer- 2 changes 10 minutes each. 
9. Kept in protein block for 10 minutes. 
10. Application of primary antibody (ER, PR, HER 2  neu) – 30 minutes. 
11. Washed in TRIS wash buffer- 2 changes 10 minutes each. 
12. Amplifier application for 15 minutes. 
13. Washed in TRIS wash buffer- 2 changes 10 minutes each. 
14. Application of secondary antibody (HRP POLYMERASE) – 20 minutes. 
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15. Washed in TRIS wash buffer- 2 changes 10 minutes each. 
16. Application of Diamino-benzidine tetrachloride (DAB) chromogen 2 - 4 
minutes. 
17. Washed in distilled water – 2 changes. 
18. Counterstaining is done with Hematoxylin for 30 seconds to impart 
background staining. 
19. Wash in running tap water. 
20. This is followed by dehydration, clearing and mounting. 
IMMUNOHISTOCHEMICAL EVALUATION 
Immuohistochemical analysis of a panel of HER2/neu, ER, PR were done 
in paraffin embedded tissue samples using  polymer HRP system based on non-
biotin polymeric technology. 5 μ thick sections from formalin fixed paraffin 
embedded tissue samples were transferred onto Poly-L-Lysine coated slides. 
Heat induced antigen retrieval was done. The antigen was bound with rabbit 
monoclonal antibody against HER2/neu, ER, PR and then detected by the 
addition of secondary antibody conjugated with horse radish peroxidase - 
polymer and diaminobenzidine substrate.  
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TABLE 8: BIOMARKERS USED IN IHC 
Antigen Species(clone) Dilution 
HER2/neu Rabbit monoclonal Ready to use 
ER, PR Rabbit monoclonal Ready  to use 
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OBSERVATION AND ANALYSIS 
 
Of the 50 patients included in the study majority of the patients were 
between 50 and 60 years. Who constituted 46% of the group. The youngest 
patient was 33years old and the oldest patient is 75 years old. 
TABLE 9: AGE DISTRIBUTION OF PATIENTS 
AGE  
(years) 
NO. OF PATIENTS (n=50) PERCENTAGE (%) 
31 – 40 9 18 
41 – 50 12 24 
51 – 60 23 46 
>60 6 12 
CHART 1: AGE DISTRIBUTION OF PATIENTS 
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DISTRIBUTION OF SAMPLES BASED ON HISTOLOGICAL 
SUBTYPES  
Of the 50 patients analysed 42 (84%) were IDC, NOS. Invasive lobular 
carcinoma constituted 6% of the group followed by papillary and mucinous 
carcinoma each constitutes 4%. Metaplastic carcinoma was the least common 
type constituting 2% of the cases.  
TABLE 10: DISTRIBUTION OF SAMPLES BASED ON 
HISTOLOGICAL SUBTYPES  
HISTOLOGICAL SUBTYPES 
NO. OF 
PATIENTS(n=50) 
PERCENTAGE 
(%) 
Invasive Ductal carcinoma, NOS 42 84 
Invasive Lobular carcinoma 3 6 
Papillary carcinoma 2 4 
Mucinous carcinoma 2 4 
Metaplastic carcinoma 1 2 
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CHART 2: DISTRIBUTION OF SAMPLES BASED ON HISTOLOGICAL 
SUBTYPES 
 
 
DISTRIBUTION OF SAMPLE BASED ON MODIFIED BLOOM 
RICHARDSON GRADE 
Modified Bloom Richardson scoring system was applied to all these 
cases. Among these cases, majority of the patients 25 (50%) were of MBR grade 
II followed 21 cases were grade III (42%) and 4 cases (8%) were under grade I. 
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TABLE 11: DISTRIBUTION OF SAMPLES BASED ON MODIFIED 
BLOOM RICHARDSON GRADE 
MBR GRADE 
NO. OF PATIENTS 
(n=50) 
PERCENTAGE (%) 
I 4 8 
II 25 50 
III 21 42 
 
CHART 3: DISTRIBUTION OF SAMPLES ACCORDING TO 
MODIFIED BLOOM RICHARDSON GRADE 
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DISTRIBUTION OF ER, PR, HER 2 / neu RECEPTORS: 
 There was an almost equal distribution of estrogen receptor positive 
(48%) and negative cases (50%), 2% of sample was lost during tissue 
processing. While analyzing the progesterone receptor status, majority of tumors 
were receptor positive (62%). Only 32% of cases did not express progesterone 
receptor and remaining 6% of samples were lost during tissue processing. 50% 
of the cases demonstrated HER-2/neu positivity and 40% of cases were negative. 
10% of samples were lost during tissue processing. 
TABLE 12: DISTRIBUTION OF ER STATUS 
ER STATUS NO. OF PATIENTS 
(n=50) 
Percentage (%) 
Positive 24 48 
Negative 25 50 
Tissue loss 1 2 
 
CHART 4: DISTRIBUTION OF ER STATUS 
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TABLE 13: DISTRIBUTION OF PR STATUS 
 
 
PR STATUS NO. OF PATIENTS 
(n=50) 
Percentage (%) 
Positive 31 62 
Negative 16 32 
Tissue loss 3 6 
 
 
CHART 5: DISTRIBUTION OF PR STATUS 
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TABLE 14: DISTRIBUTION OF HER – 2/NEU STATUS 
HER -2 / neu STATUS NO. OF PATIENTS 
(n=50) 
Percentage (%) 
Positive 25 50 
Negative 20 40 
Tissue loss 5 10 
 
 
CHART 6: DISTRIBUTION OF HER – 2/NEU STATUS 
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CORRELATION BETWEEN HISTOLOGICAL SUBTYPES AND ER, PR 
AND HER – 2: 
Among cases of IDC, NOS type, almost 50% of cases showed ER 
positivity and HER 2/neu positivity. Around 60% of cases showed PR positivity. 
Among 3 cases of invasive Lobular carcinoma, 2 cases demonstrated ER and PR 
positivity and 1 case showed HER-2/neu positivity.  Among 2 cases of papillary 
carcinoma, one case showed triple negative and the other case was ER and PR 
negative and HER-2 positive. None of the mucinous carcinoma cases showed 
HER-2neu positivity and the 1 case of metaplastic carcinoma was positive only 
for HER-2/neu.   
TABLE 15:  RELATIONSHIP BETWEEN HISTOLOGIC SUBTYPES 
AND ER, PR AND HER-2/ NEU IN 50 CASES. 
HPE DIAGNOSIS ER (+) PR (+) HER – 2/neu (+) 
IDC, NOS 21 27 22 
Inv. Lobular ca 2 2 1 
Papillary ca 0 0 1 
Mucinous ca 1 2 0 
Metaplastic ca 0 0 1 
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CHART 7: HISTOGRAM DEMONSTRATING RELATION BETWEEN 
HISTOLOGIC SUBTYPE AND RECEPTOR STATUS 
 
CORRELATION OF ER STATUS WITH MODIFIED BLOOM 
RICHARDSON  GRADE 
Among Grade I tumors 3 were ER positive, 1 were ER negative. And 
among the 25 cases of Grade II tumors, 16 were ER positive and 8 ER negative.  
Total of 21 cases belonged to Grade III tumors, among them ER positive tumors 
were 5 and 16 were ER negative. The relationship between ER status and 
histological grading was assessed using Chi square test. It revealed a significant 
association, p value: 0.009. 
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TABLE 16.  RELATIONSHIP OF ER TO MODIFIED BLOOM 
RICHARDSON GRADE 
MBR GRADE ER(+) ER(-) P value* 
Chi square test 
I 3 1  
0.009 II 16 8 
III 5 16 
 
CHART 8: HISTOGRAM SHOWING RELATIONSHIP BETWEEN ER 
STATUS AND MODIFIED BLOOM RICHARDSON GRADE. 
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CORRELATION OF PR WITH MODIFIED BLOOM RICHARDSON 
GRADE 
 All cases of grade I tumors were PR (+). Among the 25 cases of grade II 
tumors, 18 were PR (+), 4 were PR (-). Total of 21 cases of grade III tumors 9 
were positive and 12 were negative. There was a significant statistical 
association between the progesterone receptor status and the histological grade 
(p value: 0.008, Chi square test). 
 
TABLE 17.  RELATIONSHIP BETWEEN PR AND MODIFIED BLOOM 
RICHARDSON GRADE 
GRADE PR (+) PR(-) 
P value* 
Chi square test 
I 4 0  
0.008 
 
II 18 4 
III 9 12 
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CHART 9: HISTOGRAM SHOWING RELATIONSHIP BETWEEN PR 
STATUS AND MODIFIED BLOOM RICHARDSON GRADE. 
 
 
CORRELATION BETWEEN HER 2/neu AND MODIFIED BLOOM 
RICHARDSON GRADE 
 In the present study 14 HER 2(+) and 7 HER2 (-) was noted in grade II 
tumors. Among 21 grade III tumors 12 were positive and 9 were negative. The 
relationship between Her2neu status and histological grading was statistically 
significant (p value: 0.04) when assessed by Chi square test. 
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TABLE 18: CORRELATION BETWEEN HER 2/neu AND MODIFIED 
BLOOM RICHARDSON GRADE 
GRADE HER 2/neu (+) HER 2/neu(-) 
P value* 
Chi square test 
I 0 4  
0.04 
 
 
II 14 7 
III 12 9 
 
CHART 10 : HISTOGRAM SHOWING RELATIONSHIP BETWEEN 
HER2 STATUS AND MODIFIED BLOOM RICHARDSON GRADE. 
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TABLE 19: QUANTIFICATION OF IHC REAGENTS USED IN 
CONVENTIONAL VS TMA SECTIONS 
IMMUNOHISTOCHEMICAL 
REAGENT 
TMA CONVENTIONAL CONSUMPTION 
RATIO 
Primary antibody .11 IU .8 IU 1:7 
Secondary antibody .11 IU .8 IU 1:7 
Chromogen .11 IU .8 IU 1:7 
 
The conventional immunohistochemistry using full section consumes 0.8 
IU of the chemical reagents whereas only one seventh of the reagent is 
consumed by tissue microarray. 
 
 
 
 
 
 
 
 
 
Fig.3 (A) – Invasive Ductal carcinoma (NOS) - Grade III (H&E, 100x) 
 
 
Fig. 3 (B) – Mucinous carcinoma (H & E, 100x) 
 
Fig. 4(A). Grade I IDC (NOS) - showing ER (+) of score 5 in the above tumor 
(IHC, 100x) 
 
 
Fig. 4 (B) – Grade II IDC (NOS) showing intense PR (+) of score 8 in the above 
tumor (IHC, 100x) 
 
Fig. 4(C): Grade II IDC (NOS) –showing weak ER (+) of score 3 in the above 
tumor( IHC, 400x) 
 
Fig. 5(A) – IDC (NOS) Grade II showing weak PR (+) of score 5 in the above 
tumor (IHC, 100x) 
 
Fig. 5 (B) – Grade II IDC (NOS) showing PR (+) of score 8 in the above tumor 
(IHC, 400x) 
 
 
Fig. 6 (A) – Grade III IDC (NOS) showing strong HER 2 (+) of score 3 in the 
above tumor (IHC, 100x) 
 
Fig. 6(B) – Grade II – IDC (NOS) showing weak HER 2 (+) of score 2 in the 
above tumor (IHC, 400x) 
 
 
Fig. 6(C) – Grade III – IDC (NOS) showing intense HER 2 (+) of score 3 in the 
above tumor (IHC, 400x)  
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DISCUSSION 
 
The present study included 50 cases of histologically diagnosed Invasive 
breast carcinoma and Modified Bloom and Richardson grading system was 
applied for all these cases.  Tissue Microarray was constructed for all these 50 
cases on seven blocks and they were subjected to Immunohistochemical analysis 
to study ER, PR and HER 2 status in these tumors. 
In the study done by Piero et al,(86)  IDC (NOS) constituted 94.3% and 
ILC 5.7% of cases where as in Zafrani B et al study,(87)  IDC (NOS) and ILC 
constituted 77% and 18% respectively. In the study conducted by Onitilo et al(88), 
IDC (NOS) was 72.7% and ILC was 12.1%. In the present study out of 50 cases, 
42 were IDC (NOS) which constituted 84% and 3 were ILC which constituted 
6% which is comparable to the previous studies quoted. Other subtypes of breast 
carcinomas had varied incidence in different studies and in the present study, 
remaining cases include papillary carcinoma (4%), mucinous carcinoma (4%) 
and metaplastic carcinoma (2%). 
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TABLE 20: COMPARATIVE STUDY OF ER STATUS IN DIFFERENT 
TYPE OF BREAST CARCINOMA 
ER positivity (%) 
 Lap P et al(89) Ayadi et al(90) Present study 
IDC, NOS 71.58% 61.1% 50% 
ILC 93.3% 50% 66.66% 
Mucinous ca 100% 60% 50% 
Papillary ca - - 0 
Metaplastic ca 0 - 0 
 
TABLE 21: COMPARATIVE STUDY OF PR STATUS IN DIFFERENT 
TYPE OF BREAST CARCINOMA 
PR positivity (%) 
 Lap P et al(89) Ayadi et al(90) Present study 
 
IDC, NOS 47.38% 53.8% 64.28% 
ILC 60.2% 50% 66.66% 
Mucinous ca 70% 60% 100% 
Papillary ca - - 0 
Metaplastic ca 0 - 0 
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TABLE 22: COMPARATIVE STUDY OF HER-2 STATUS IN 
DIFFERENT TYPE OF BREAST CARCINOMA 
HER-2 / neu positivity (%) 
 Lap P et al(89) Ayadi et al(90) Present study 
 
IDC, NOS 17.54% 16.8% 52.38% 
ILC 0.8% 16.7% 33.33% 
Mucinous ca 0 0 0 
Papillary ca - - 50% 
Metaplastic ca 0 - 100% 
 
In the study done by Lap P et al(89) and Ayadi et al(90) demonstrated high 
ER, PR positivity and low HER-2 expression with IDC (NOS), Invasive Lobular 
carcinoma and mucinous carcinoma. In the present study, IDC (NOS) showed high 
PR positivity but ER positivity was comparatively lower and HER-2 positivity was 
higher than above studies quoted whereas in Lobular carcinoma and Mucinous 
carcinoma, receptor status was almost equal to that of the studies quoted above 
(Table 20, 21 & 22). In the present study both the Papillary carcinoma was negative 
for ER and PR but one papillary carcinoma was positive for HER-2 which was 
similar to the above studies quoted. In the present study one case of Metaplastic 
carcinoma was negative for ER and PR, similar to the study of Lap P et al(89)   
(Table 20 & 21). 
 In the studies conducted by Zafrani et al,(87)  Onitilo AA et al (88) and Piero 
G et al,(86) the most common tumors were grade II which constituted 40%, 
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38.4% and 37% respectively. In present study also majority were grade II tumors 
which constituted 50% of the cases. 
In the study done by Ayadi et al (90), 72.2% of ER positive cases were 
grade I and II whereas 22.5% of ER (+) cases were grade III tumors. In the 
present study, out of 50 cases, 65.51% of ER positive cases were grade I and II, 
whereas 23.8% of ER (+) cases were grade III tumors. In the present study the 
relationship between ER expression and histological grading was statistically 
significant (p value: 0.009). In Ayadi et al(90) study, 61.4% of PR (+) cases were 
grade I and II tumors and 27.5% of PR (+) cases were grade III tumors. In the 
present study, 75.86% cases were grade I and II and 42.85% cases were grade III 
tumors (Table.23). In the present study, the relationship between PR expression 
and histological grading was statistically significant (p value: 0.008). 
 In the study done by Ayadi et al(90), 14.8% of HER 2 (+) cases were grade 
I and II tumors and 27.5% cases of HER 2 cases were grade III tumors whereas 
in the present study 48.27% of HER 2 (+) cases were in grade I and II and 
57.14% cases of HER 2 (+) were in grade III (Table.23). In the present study the 
relationship between ER expression and histological grading was statistically 
significant (p value: 0.04). 
 
 
 
82 
 
TABLE 23:  COMPARISON OF STUDIES BASED ON ER, PR & HER 2 
AND HISTOLOGICAL GRADES 
 Ayadi et al(90) Present study 
Histological grade ER (+) PR (+) HER 2(+) ER(+) PR(+) HER2(+)
Grade I and II 72.2% 61.4% 14.8% 65.1% 75.86% 48.27% 
Grade III 22.5% 27.5% 27.5% 23.8% 42.85% 57.14% 
 
 Huang JH et al (91) and Ayadi L et al (90), have shown that grade I and 
grade II tumors showed increased expression of hormone receptors when 
compared to grade III tumors.  In Ayadi et al, HER 2 expression was noted in 
14.8% of grade I and II tumors whereas in the present study, HER 2 (+) cases 
was higher which constituted 48.27% (Table.23).  
In the study done by Onitilo AA et al(88), overall triple negative cases 
were 13.4% whereas in the present study, triple negative cases were 10% of all 
cases. 
According to Richter J et al (92), tissue loss due to technical problem 
ranged between 15-33%. D H Zhang et al(93), in his study observed tissue loss of 
4% whereas in the present study overall tissue loss accounted to 10.66%. 
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To analyse single conventional tissue section immunohistochemically, 
minimum of two drops (0.8 IU) of chemical reagents which includes primary 
antibody, secondary antibody and DAB chromogen are required. Hence, a single 
tissue section when used conventionally consumes 0.8 IU of the reagent whereas 
in TMA, the same quantity has been used to analyze seven cores taken from 
seven different cases. So TMA, apart from having the advantage of parallel 
analysis of multiple sections, also decreases the time taken for the IHC 
procedure and the amount of chemical reagents used(92). In this way, the use of 
immunohistochemical analysis in Invasive breast carcinoma by tissue microarray 
is helpful for economical and rapid study of receptor status. 
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SUMMARY 
 
This study was conducted in Department of Pathology, Tirunelveli 
Medical College from 50 cases of invasive breast carcinoma. Histological 
grading was done for all these cases according to Modified Bloom Richardson 
and the paraffin embedded tissue blocks from these cases were retrieved.  Areas 
of invasive carcinoma were identified using corresponding haematoxylin and 
eosin stained slides and these areas were cored using bone marrow needle and 
transferred to recipient blocks. Thus Tissue microarray was constructed 
manually for 50 cases in 7 blocks. Array sections from these 7 blocks were 
obtained and they were subjected to immunohistochemical analysis using ER, 
PR and HER 2, of which 10.66% had tissue loss.  
Among 50 cases, 42 cases (84%) were Invasive ductal carcinoma (NOS) 
type, 3 cases (6%) were Lobular carcinoma, 2 cases (4%) were Papillary, and 2 
cases were (4%)  Mucinous carcinoma and 1 (2%) Metaplastic carcinoma.  
Among 50 cases, ER and PR were positive in 24 cases (48%) and 31 
cases (62%) respectively. HER- 2 over expression was seen in 25 cases (50%). 
Among the most common histologic subtype i.e., IDC (NOS), ER, PR 
and HER-2 were expressed in 50%, 64.28% and 52.38% respectively. 
Among 50 cases, 4 cases (8%) of grade I tumors, 25 cases (50%) were 
under grade II tumors, and 21 cases (42%) were grade III.  
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Among the 50 cases, grade I and II tumors showed higher expression of 
hormone receptors whereas grade III tumors showed higher expression of          
HER-2. 
Statistically significant values were noted between histological grade and 
ER, PR and HER-2 status. 
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CONCLUSION 
 
¾ The process of immunohistochemistry using conventional tissue section 
consumes more reagents, also requires control and standardisation for 
each batch which is not needed while using tissue microarray.  
¾ Immunohistochemical analysis with a panel of markers using tissue 
microarray greatly reduces time and manual labour. 
¾ By taking representative cores from different cases and performing IHC 
on them on a single slide proved to be economical. 
¾ Tissue loss due to technical problems can be overcome by following 
standard protocols or by obtaining more number of tissue cores. 
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ANNEXURE-I 
WHO HISTOLOGICAL CLASSIFICATION OF TUMORS OF BREAST 
Epithelial tumors 
Invasive ductal carcinoma,not otherwise specified 
¾ Mixed type carcinoma 
¾ Pleomorphic carcinoma 
¾ Carcinoma with osteoclast like giant cells 
¾ Carcinoma with choriocarcinomatous features 
¾ Carcinoma with melanotic features 
Invasive lobular carcinoma 
Tubular carcinoma 
Invasive cribriform carcinoma 
Medullary carcinoma 
Mucinous carcinoma and other tumors with abundant mucin 
¾ Mucinous carcinoma 
¾ Cystadenocarcinoma and columnar cell mucinous carcinoma 
¾ Signet ring carcinoma 
Neuroendocrine tumors 
¾ Solid neuroendocrine carcinoma 
¾ Atypical carcinoid tumor 
¾ Small cell/oat cell carcinoma 
¾ Large cell neuroendocrine carcinoma 
 
 
 
Invasive papillary carcinoma 
Invasive micropapillary carcinoma 
Apocrine carcinoma 
Metaplastic carcinoma 
¾ Pure epithelial metaplastic carcinoma 
¾ Squamous cell carcinoma 
¾ Adeno carcinoma with spindle cell metaplasia 
¾ Adenosquamous carcinoma 
¾ Mucoepidermoid carcinoma 
¾ Mixed epithelial/mesenchymal metaplastic carcinoma 
Lipid rich carcinoma 
Secretory carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen rich clear cell carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Lobular neoplasia 
¾ Lobular carcinoma in situ 
Intraductal proliferative lesions 
¾ Usual ductal hyperplasia 
¾ Flat epithelial atypia 
 
 
¾ Atypical ductal hyperplasia 
¾ Ductal carcinoma on situ 
Microinvasive carcinoma 
Intraductal papillary neoplasm 
¾ Central papilloma 
¾ Peripheral papilloma 
¾ Atypical papilloma 
¾ Intraductal papillary carcinoma 
¾ Intracystic papillary carcinoma 
Adenosis including variants 
¾ Sclerosing Adenosis 
¾ Apocrine Adenosis 
¾ Blunt duct Adenosis 
¾ Microglandular Adenosis 
¾ Adenomyoepithelial Adenosis 
Radial scar/complex sclerosing lesion 
Adenomas 
¾ Tubular Adenoma 
¾ Lactating Adenoma 
¾ Apocrine Adenoma 
¾ Pleomorphic Adenoma 
¾ Ductal Adenoma 
 
 
 
Myoepithelial lesions 
Myoepitheliosis 
Adenomyoepithelial adenosis 
Adenomyoepithelioma 
Malignant myoepithelioma 
Mesenchymal tumors 
Hemangioma 
Angiomatosis 
Hemangiopericytoma 
Pseudoangiomatous stromal hyperplasia 
Myofibroblastoma 
Fibromatosis 
Inflammatory myofibroblastic tumor 
Lipoma 
Angiolipoma 
Granular cell tumor 
Neurofibroma 
Schwannoma 
Angiosarcoma 
Liposarcoma 
Rhabdomyosarcoma 
Osteosarcoma 
Leiomyoma 
 
 
Leiomyosarcoma 
Fibroepithelial tumors 
Fibroadenoma 
Phyllodes tumor 
¾ Benign 
¾ Borderline 
¾ Malignant 
Periductal stromal sarcoma,low grade 
Mammary hamartoma 
Tumors of the nipple 
Nipple adenoma 
Syringomatous adenoma 
Pagets disease of nipple 
Malignant lymphoma 
Diffuse large B cell lymphoma 
Burkitt’s lymphoma 
Extranodal marginal zone B Cell lymphoma 
Follicular lymphoma 
Metastatic tumors 
Tumors of the male breast 
Gynaecomastia , Carcinoma :invasive, insitu 
 
 
 
 
ANNEXURE 2 
PROCESSING FOR IMMUNOHISTOCHEMISTRY 
• Section cutting and incubation is followed by Xylene wash (2 changes) 
for 10 minutes each. 
• Rehydrated in graded alchohol containing 100%, 80%, 70% for ten 
minutes each. 
• Rinsed in distilled water for 2 minutes. 
• Antigen retrieval. 
• Cooling for 15 minutes. 
• Washed in TRIS wash buffer- 2 changes 5 minutes each. 
• Treated with peroxide block for 5 minutes. 
• Washed in TRIS wash buffer- 2 changes 10 minutes each. 
• Kept in protein block for 10 minutes. 
• Application of primary antibody (ER, PR, HER 2  neu) – 30 minutes. 
• Washed in TRIS wash buffer- 2 changes 10 minutes each. 
• Amplifier application for 15 minutes. 
• Washed in TRIS wash buffer- 2 changes 10 minutes each. 
• Application of secondary antibody (HRP POLYMERASE) – 20 minutes. 
• Washed in TRIS wash buffer- 2 changes 10 minutes each. 
• Application of Diamino-benzidine tetrachloride (DAB) chromogen 2 - 4 
minutes. 
• Washed in distilled water – 2 changes. 
 
 
• Counterstaining is done with Hematoxylin for 30 seconds to impart 
background staining. 
• Wash in running tap water. 
• This is followed by dehydration, clearing and mounting. 
 
BUFFER PREPARATIONS 
1) Tris – EDTA Buffer: - PH- 9.0 
Tris                 - 6.05 gm 
EDTA            - 0.744 gm 
           Distilled water   - 1000 ml 
2) Citrate buffer :-   p H-6.2  
Citrate  - 1.92 gm 
          Distilled water -1000 ml 
3) Tris wash buffer 
Tris                       -  0.605 gm 
            Sodium chloride  -  8 gm 
            1 N Hcl                -  4ml 
            Distilled water     -  1000 ml 
 
 
 
 
PRECAUTIONS 
1. The glasswares used should be dry and clean. 
2. All the buffers used should be prepared fresh and the pH should be 
adjusted according to the preferred pH. 
3. The staining procedures are never allowed to dry so they are performed 
under a humidity chamber. 
4. DAB chromogen should be handled and disposed carefully as it is a 
carcinogen. 
5. Primary, secondary antibody, DAB chromogen, peroxidase block, 
amplifier , everything should be stored at 4-6ºC 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE 3 
ALLRED SCORING GUIDELINES FOR ER AND PR 
Proportion score 
           Proportion score is done by calculating the proportion of tumor cells with     
positive nuclear staining 
0 = no nuclear staining 
1 = <1% nuclear staining 
  2 = 1%-10% nuclear staining, 
  3 = 11%-33% nuclear staining 
4 = 34%-66% nuclear staining  
5 = 67%-100% nuclear staining 
Intensity of staining 
        0 = no staining 
         1 = weak staining 
        2 = moderate staining  
        3 = strong staining 
Total score =proportion score + intensity score (0 to 8) 
Interpretation:. 
0,2  -  Negative 
≥ 3  -  Positive   
 
 
GRADING OF THE IMMUNOHISTOCHEMICAL STAINING FOR HER 
2 / NEU OVEREXPRESSION 
Score Staining Pattern HER 2 / neu protein 
overexpression assessment 
0 
 
No staining at all or very slight partial 
membrane staining in less than 10% of 
tumor cells. 
Negative 
1+ 
 
Faint barely perceptible membrane staining 
in more than    10%     of tumor cells. Cells 
stained in only part of the membrane. 
Negative 
2+ 
 
Weak to moderate complete membrane 
staining observed in more than 10% of 
tumor cells. 
Weakly Positive 
3+ Strong complete membrane staining in more  
than 30% of tumor cells 
Strongly Positive 
 
 
 
 
 
 
 
MASTER CHART 
S.NO HPE NO AGE SEX 
HISTOPATHOLOGICAL 
DIAGNOSIS 
MBR GRADING 
ER STATUS BY ALLRED SCORING 
SYSTEM 
PR STATUS BY ALLRED SCORING SYSTEM 
HER 2/ NEU BY ASCO 
SCORING SYSTEM 
            PROPORTION INTENSITY SCORE PROPORTION INTENSITY SCORE   
1 391/ 15 60 F IDC, NOS II 5 2 Positive 3 2 Positive Positive 
2 400/ 15 36 F IDC, NOS II 4 2 Positive 3 2 Positive Positive 
3 271 /15 67 F IDC, NOS III 3 2 Positive 4 2 Positive Positive 
4 541/ 15 39 F IDC, NOS III 2 2 Positive 2 1 Positive Negative 
5 1238/ 15 45 F IDC, NOS II 5 2 Positive 5 2 Positive Positive 
6 139/ 15 36 F IDC, NOS II 3 2 Positive 3 2 Positive Negative 
7 198/ 15 60 F IDC, NOS I 3 1 Positive 2 2 Positive Negative 
8 2328/ 14 50 F Papillary carcinoma III 0 0 Negative 0 0 Negative Positive 
9 1717/ 15 52 F IDC, NOS III 0 0 Negative 0 0 Negative Positive 
10 1510/ 15 60 F Metaplastic carcinoma III 0 0 Negative 0 0 Negative Positive 
11 1075/ 15 56 F IDC, NOS II 0 0 Negative 2 2 Positive Positive 
12 1176/ 15 63 F IDC, NOS III 0 0 Negative 2 2 Positive Positive 
13 1741/ 15 57 F IDC, NOS II 0 0 Negative 2 1 Positive Positive 
14 1760/ 15 50 F IDC, NOS III 0 0 Negative 0 0 Negative Negative 
15 1629/ 14 60 F IDC, NOS II 4 2 Positive 2 1 Positive Negative 
16 1820/ 15 35 F Mucinous carcinoma I 3 2 Positive 4 3 Positive Negative 
17 3184/ 14 53 F IDC, NOS II 3 1 Positive 3 3 Positive Positive 
18 1820/ 14 35 F IDC, NOS II 0 0 Negative 0 0 Negative Positive 
19 2227/ 14 60 F IDC, NOS II 0 0 Negative 0 0 Negative Positive 
20 1637/ 14 50 F IDC, NOS II 5 2 Positive 4 2 Positive Negative 
21 2411/ 14 45 F IDC, NOS II 0 0 Negative 0 0 Negative Positive 
22 2053/ 14 41 F Invasive Lobular carcinoma II Tissue Loss Tissue Loss Tissue loss 
23 244/ 15 49 F IDC, NOS III 0 0 Negative 0 0 Negative Negative 
24 3264/ 14 52 F Mucinous carcinoma I 0 0 Negative 2 1 Positive Negative 
 
 
25 1651/ 14 65 F Papillary carcinoma III 0 0 Negative 2 1 Negative Negative 
26 858/ 14 61 F IDC, NOS III 0 0 Negative 2 1 Positive Positive 
27 615/ 15 58 F IDC, NOS II 0 0 Negative Tissue Loss Tissue loss 
28 977/ 14 46 F IDC, NOS II 3 1 Positive 2 1 Positive Negative 
29 1616/ 15 33 F IDC, NOS II 2 1 Positive Tissue Loss Tissue loss 
30 614/ 15 40 F IDC, NOS II 4 3 Positive 3 2 Positive Negative 
31 762/ 15 55 F Invasive Lobular carcinoma II 5 3 Positive 2 2 Positive Positive 
32 829/ 15 57 F IDC, NOS III 0 0 Negative 0 0 Negative Positive 
33 726/ 15 44 F IDC, NOS II 0 0 Negative 0 0 Negative Positive 
34 854/ 14 58 F IDC, NOS III 0 0 Negative 0 0 Negative Positive 
35 494/ 14 64 F IDC, NOS III 0 0 Negative 0 0 Negative Negative 
36 2067/ 14 45 F IDC, NOS II 2 2 Positive 2 1 Positive Positive 
37 196/ 15 40 F IDC, NOS II 0 0 Negative 2 1 Positive Positive 
38 345/ 15 39 F IDC, NOS III 5 3 Positive 2 1 Positive Negative 
39 124/ 15 60 F IDC, NOS III 4 3 Positive 0 0 Negative Negative 
40 199/ 15 55 F IDC, NOS II 3 1 Positive 2 1 Positive Negative 
41 153/ 15 75 F IDC, NOS III 0 0 Negative 3 2 Positive Positive 
42 106/ 15 36 F IDC, NOS III 0 0 Negative 0 0 Negative Negative 
43 2608/ 14 57 F IDC, NOS III 3 2 Positive 3 2 Positive Tissue loss 
44 2979/ 14 53 F IDC, NOS III 0 0 Negative 0 0 Negative Positive 
45 2850/ 14 60 F IDC, NOS III 0 0 Negative 4 2 Positive Positive 
46 3137/ 14 55 F IDC, NOS II 4 2 Positive 3 2 Positive Tissue loss 
47 2851/ 14 43 F IDC, NOS I 5 3 Positive 4 2 Positive Negative 
48 2666/ 14 54 F Invasive Lobular carcinoma II 3 1 Positive 5 3 Positive Negative 
49 3315/ 14 60 F IDC, NOS III 0 0 Negative 5 2 Positive Negative 
50 3119/ 14 42 F IDC, NOS II 5 2 Positive 4 2 Positive Positive 
 
